Work

In Situ Programming of CAR T Cells

Year: 2021

Type: review

Abstract: Gene therapy makes it possible to engineer chimeric antigen receptors (CARs) to create T cells that target specific diseases. However, current approaches require elaborate and expensive protocols to manufacture engineered T cells ex vivo, putting this therapy beyond the reach of many patients who might benefit. A solution could be to program T cells in vivo. Here, we evaluate the clinical need for in situ CAR T cell programming, compare competing technologies, review current progress, and provide a perspective on the long-term impact of this emerging and rapidly flourishing biotechnology field.

Source: Annual Review of Biomedical Engineering

DOI: 10.1146/annurev-bioeng-070620-033348

Authors: Neha N. Parayath, Matthias T. Stephan

Institutions: Fred Hutch Cancer Center, University of Washington

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funder: National Cancer Institute